It has also been linked to increased GLP-1 production, promoting better appetite regulation, blood sugar control, and fat metabolism
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patients outcome
Similarly, a JAMA study found that patients using GLP-1 agonists for weight loss faced significantly higher risks of pancreatitis, gastroparesis, and bowel obstruction
Moreover, LC administrated for 2 weeks suppresses atrogin-1 messenger RNA (mRNA) level in suspended rats hindlimb [35], and only 7 days of LC administration downregulates MuRF-1 and atrogin-1 mRNAs reducing muscle wasting in a rat model of cancer cachexia [32]
The indirect connection may relate to: The rate of weight loss achieved with Saxenda Changes in dietary patterns during treatment Alterations in fluid balance or hydration status Pre-existing risk factors that coincide with obesity Patients concerned about gout whilst taking Saxenda should discuss their individual risk profile with their GP or prescribing clinician, particularly if they have a personal or family history of gout or elevated uric acid levels